NCCN 2021 Conference Highlights: Elevating Racial Equity in Cancer Care
The National Comprehensive Cancer Network (NCCN) 2021 Annual Conference convened virtually March 18-20, drawing attendees from more than 40 countries...
Traditional CROs fragment device development with costly hand-offs and learning curves. Veranex unites the essential disciplines for medical device & diagnostic development under one roof from sketch to evidence-generation to market launch.
All connected. All aligned. All accelerating your path to market—delivering breakthrough devices and diagnostics that improve patient lives sooner.
Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.
Purpose-built solutions. Proven results. User & Patient-centered innovation.
Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity. Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.
We are the Innovation CRO.
Legacy of excellence. Proven execution. Patient impact accelerated.
2 min read
Gary Keeler : Jan 20, 2023 4:12:28 PM
It should come as no surprise that conducting a clinical trial is expensive. Just how expensive depends on the phase and design of the trial, with costs typically increasing with phase and complexity. A recent Tufts study has found that Phase III oncology trial budgets exceeded $65 million while non-oncology trial budgets were at ~$54 million. [1] Other sources have estimated even higher costs. [2]
Sponsors are interested in keeping their budgets stable and reigning in out-of-scope costs that can skyrocket budgets due to study changes, including delayed enrollment, protocol changes and erroneous initial budget estimates. What are some of the challenges and subsequent tips to keeping a trial on-time and within budget? Let’s start with upfront activities.
Trials that are outsourced to CROs for all or a portion of services can expect the service costs within the following categories, presented in descending order of a typical study budget:
Budgets are drawn up for activities within each of these areas, based on a near final protocol and comprise the ‘scope of work.’ A CRO will work with sponsors to develop a budget proposal based on an agreed upon scope of work. This can be a ballpark, preliminary estimate or a detailed appraisal with corresponding tasks and activities.
The National Comprehensive Cancer Network (NCCN) 2021 Annual Conference convened virtually March 18-20, drawing attendees from more than 40 countries...
Prediction: In 10 years, clinical trials will be nearly paperless. And clinical trial historians will note that the coronavirus pandemic was the...
The clinical research landscape is rapidly evolving, placing increased importance on robust and compliant clinical data management services (CDMS)....